Revenue
2021
BioAtla, Inc. (BCAB)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $300,000 | — | — |
| Research & development | $43.6M | $63.1M | $103.7M | $79.3M | $58.3M | $19.9M | $25.9M |
| Operating expenses | $61.3M | $84.9M | $129.7M | $108.1M | $96.7M | $30.5M | $33.5M |
| Operating income | −$59.3M | −$73.9M | −$129.7M | −$108.1M | −$96.4M | −$30.1M | −$28.3M |
| EBITDAderived | −$58.9M | −$73.0M | −$128.5M | −$106.9M | −$95.1M | −$29.1M | −$27.4M |
| Net income | −$59.6M | −$69.8M | −$123.5M | −$106.5M | −$95.4M | −$35.9M | −$29.9M |
| Basic EPSper diluted share | -$1.01 | -$1.44 | -$2.58 | -$2.74 | -$2.76 | -$3.19 | — |
| Diluted EPSper diluted share | -$1.01 | -$1.44 | -$2.58 | -$2.74 | -$2.76 | -$3.19 | — |